ENLIVEN THERAPEUTICS INC (ELVN)
US29337E1029 - Common Stock
Commit To Purchase Enliven Therapeutics At $10, Earn 11.2% Annualized Using Options
The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Thursday's session: gap up and gap down stocks
Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
Achieved initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients, which compares favorably to precedent Phase 1 trials of...
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors
BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision...
Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024
BOULDER, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision...
Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates
Financing includes participation from new and existing investors Net proceeds, along with existing cash, cash equivalents and marketable securities, are...
ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q4 2023
ELVN stock results show that Enliven Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Enliven Therapeutics (NASDAQ:ELVN) just reported results for the fourth quarter...
Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
Initial proof of concept data from Phase 1a trial evaluating ELVN-001 in adults with chronic myeloid leukemia (CML) is expected in the second quarter of 2024
Enliven Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
BOULDER, Colo., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology focused on the...
Commit To Purchase Enliven Therapeutics At $15, Earn 18.4% Annualized Using Options
Enliven Therapeutics GAAP EPS of -$0.51 (NASDAQ:ELVN)
Enliven Therapeutics press release (NASDAQ:ELVN): Q3 GAAP EPS of -$0.51.As of September 30, 2023, the Company had cash, cash equivalents and marketable...
RSI Alert: Enliven Therapeutics (ELVN) Now Oversold
Commit To Buy Enliven Therapeutics At $10, Earn 28.5% Annualized Using Options
Enliven Therapeutics 10% owner disposes of ~$3M worth of shares (NASDAQ:ELVN)
Enliven Therapeutics' 10% owner Kush Parmar sells $3M worth of shares, causing a 2.6% drop in stock price.
Enliven Therapeutics Breaks Below 200-Day Moving Average - Notable for ELVN
Enliven Therapeutics is Now Oversold (ELVN)
7 A-Rated Biotech Stocks for Your August Buy List
Investing in biotech stocks means accepting a long R&D window, but the rewards when your A-rated biotech stocks come through are huge.
Enliven Therapeutics GAAP EPS of -$0.41 beats by $0.04 (NASDAQ:ELVN)
Enliven Therapeutics press release (ELVN): Q2 GAAP EPS of -$0.41 beats by $0.04. As of June 30, 2023, the Company had cash, cash equivalents and marketable securities totaling...
Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
Continued progress of parallel lead programs, ELVN-001 and ELVN-002, through dose escalation in Phase 1 trials, with initial proof of concept data for both...
Enliven Therapeutics to Present at Two Upcoming Investor Conferences
BOULDER, Colo., May 31, 2023 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology company focused...
Enliven Therapeutics GAAP EPS of -$0.80 misses by $0.28 (NASDAQ:ELVN)
Enliven Therapeutics press release (ELVN): Q1 GAAP EPS of -$0.80 misses by $0.28.Ended the first quarter 2023 with cash and cash equivalents of approximately $292 million, which...
7 Biotech Stocks Sitting in the Sweet Spot
Biotech stocks have the potential for massive profits if their companies are successful in developing drugs that are safe and marketable.
Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 Million
Combined company will be focused on advancing Enliven’s clinical-stage pipeline of precision oncology programs Shares to trade on Nasdaq under the new...